Semi-solid phase assay for the alternative complement pathway activity assessment (AP100).

Semi-solid phase assay for the alternative complement pathway activity assessment (AP100). J Immunoassay Immunochem. 2019 Nov 27;:1-8 Authors: Kerboua KE, Djenouhat K Abstract Since the introduction of the most expensive drug in the world (Eculizumab) in the therapeutic arsenal of many diseases involving the alternative complement pathway (ACP) in their pathophysiology, the unmet need to perform simple ACP assays affordable for all countries has become one of the major challenges of the contemporary medicine. The assay currently used is AH50, despite it still challenging for several laboratories. This educational chapter consists of a detail protocol of standardized hemolytic assay AP100 and aims to help clinical laboratories over the world and especially those of the developing and low income countries to perform it. The procedure is essentially the same as for the timed lysis assay and dilution methods (AP50) except the concentration of ACP buffer and the chicken erythrocyte density used to make the gels. In clinical field, AP100 has at least nine applications in disease diagnosis and follow-up. AP100 has many advantages over the AH50 as it is more reliable for the Eculizumab monitoring and more practical with a purpose to be stored and transported for several weeks. AP100 is a portable and easy to use device both at the bedside and in the companion medical care. PMID: 31771421 [PubMed - as supplied by publisher]
Source: Journal of Immunoassay and Immunochemistry - Category: Biochemistry Tags: J Immunoassay Immunochem Source Type: research

Related Links:

CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
FDA has granted Emergency Use Authorization (EUA) to Battelle's CCDS Critical Care Decontamination System for processing up to 80,000 respirator masks per system each day. CCDS employs concentrated, vapor-phase hydrogen peroxide (VPHP) for decontamination. The system has been validated to decontaminate masks of SARS-CoV-2, the company reported. The masks are placed on shelves inside a container, and a portable, external VPHP system is hooked up to the outside of container. The system was first envisioned by Battelle as part of a study commissioned by FDA in 2015. That study involved determining the feasibility of N95 respi...
Source: MDDI - Category: Medical Devices Authors: Tags: Sterilization Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Jorge A Alfaro-Murillo, Marí L Ávila-Agüero, Meagan C Fitzpatrick, Caroline J Crystal, Luiza-Helena Falleiros-Arlant, Alison P Galvani
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Stephen W Russell, Brian T Garibaldi, Andrew Elder, Abraham Verghese
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s):
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Fathiah Zakham, Olli Vapalahti, Hilal A Lashual
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Renato D Lopes, Claudio Gimpelewicz, John J V McMurray
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Genichi Sugihara, Nori Takei
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Gorka Orive, Unax Lertxundi
Source: The Lancet - Category: General Medicine Source Type: research
More News: Biochemistry | Education